SCHEMBL8938150

SCHEMBL8938150

CCc1ccc(CN2CCC(Oc3cc4cc[nH]c(=O)c4cc3Cl)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 2/20 0.57
ROCK1 Q13464 2/20 0.43
ADRB2 P07550 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ROCK2 O75116 2/20 0.41
PRKACA P17612 4/20 0.40
PRKACG P22612 3/20 0.40
PRKACB P22694 3/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
ENPP2 Q13822 2/20 0.40
MCHR1 Q99705 2/20 0.40
PRKCD Q05655 1/20 0.39
PRKG1 Q13976 1/20 0.39
PKN1 Q16512 1/20 0.39
PKN2 Q16513 1/20 0.39
AAK1 Q2M2I8 1/20 0.39
CDC42BPA Q5VT25 1/20 0.39
Q6ZSR9 Q6ZSR9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8935003 0.92 MAP2K1 (0.57) MAP2K1ROCK1ROCK2PRKACAPRKACG
SCHEMBL8938278 0.92 MAP2K1 (0.59) MAP2K1ROCK1ROCK2PRKACAPRKACG
SCHEMBL8938176 0.90 MAP2K1 (0.55) MAP2K1ROCK1MEN1KMT2AROCK2
SCHEMBL8938170 0.90 MAP2K1 (0.55) MAP2K1ROCK1MEN1KMT2AROCK2
SCHEMBL8934981 0.90 MAP2K1 (0.59) MAP2K1ROCK1ROCK2PRKACAPRKACG
SCHEMBL8938220 0.89 MAP2K1 (0.54) MAP2K1ROCK1ROCK2PRKACAPRKACG
SCHEMBL8934996 0.89 MAP2K1 (0.58) MAP2K1ROCK1ROCK2PRKACAPRKACG
SCHEMBL8935056 0.89 MAP2K1 (0.62) MAP2K1ROCK1ROCK2PRKACAPRKCD
SCHEMBL8935015 0.89 MAP2K1 (0.53) MAP2K1ROCK1
SCHEMBL8938179 0.88 MAP2K1 (0.57) MAP2K1ROCK1ROCK2PRKACAPRKACG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385047-B1 Piperidinyl-substituted isoquinolone derivatives SANOFI SA (FR) 2013-05-29 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 MAP2K1 1916/4885ROCK1 8/4885ADRB2 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.